Trial · NCT00560235
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Figitumumab 30 mg/kg (Phase 2) | 14.2 | 95% Confidence Interval 8.1 to 22.3 | percentage of participants | |
| Progression-Free Survival (PFS) | Figitumumab 30 mg/kg (Phase 2) | 1.9 | 95% Confidence Interval 1.8 to 2.1 | months | |
| Overall Survival (OS) | Figitumumab 30 mg/kg (Phase 2) | 8.9 | 95% Confidence Interval 7.2 to 10.8 | months | |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | Cycle 1 (n=4, 6, 21) | 513.2 | Geometric Coefficient of Variation 42 | milligrams per liter (mg/L) |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 30 mg/kg Dose Escalation (Phase 1) | Cycle 1 (n=4, 6, 21) | 1075 | Geometric Coefficient of Variation 21 | milligrams per liter (mg/L) |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 30 mg/kg Dose Extension (Phase 1B) | Cycle 1 (n=4, 6, 21) | 975.6 | Geometric Coefficient of Variation 26 | milligrams per liter (mg/L) |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | Cycle 5 (n=2, 2, 8) | 729.0 | Geometric Coefficient of Variation 47 | milligrams per liter (mg/L) |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 30 mg/kg Dose Escalation (Phase 1) | Cycle 5 (n=2, 2, 8) | 1133 | Geometric Coefficient of Variation 9 | milligrams per liter (mg/L) |
| Maximum Observed Plasma Concentration (Cmax) | Figitumumab 30 mg/kg Dose Extension (Phase 1B) | Cycle 5 (n=2, 2, 8) | 1043 | Geometric Coefficient of Variation 47 | milligrams per liter (mg/L) |
| Minimum Observed Plasma Trough Concentration (Cmin) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | 389.0 | mg/L | ||
| Minimum Observed Plasma Trough Concentration (Cmin) | Figitumumab 30 mg/kg Dose Escalation (Phase 1) | 345.0 | mg/L | ||
| Minimum Observed Plasma Trough Concentration (Cmin) | Figitumumab 30 mg/kg Dose Extension (Phase 1B) | 283.6 | Geometric Coefficient of Variation 53 | mg/L | |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | Cycle 1 (n=4, 6, 21) | 513.2 | Geometric Coefficient of Variation 42 | mg/L |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 30 mg/kg Dose Escalation (Phase 1) | Cycle 1 (n=4, 6, 21) | 1075 | Geometric Coefficient of Variation 21 | mg/L |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 30 mg/kg Dose Extension (Phase 1B) | Cycle 1 (n=4, 6, 21) | 975.6 | Geometric Coefficient of Variation 26 | mg/L |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | Cycle 5 (n=2, 2, 8) | 729.0 | Geometric Coefficient of Variation 47 | mg/L |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 30 mg/kg Dose Escalation (Phase 1) | Cycle 5 (n=2, 2, 8) | 1133 | Geometric Coefficient of Variation 9 | mg/L |
| Plasma Concentration at End of Infusion (Cendinf) | Figitumumab 30 mg/kg Dose Extension (Phase 1B) | Cycle 5 (n=2, 2, 8) | 1043 | Geometric Coefficient of Variation 47 | mg/L |
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | Figitumumab 20 mg/kg Dose Escalation (Phase 1) | 423000 | milligram*hour per liter (mg*hr/L) | ||
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) | Figitumumab 30 mg Dose Escalation (Phase 1) | 475000 | milligram*hour per liter (mg*hr/L) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00560235/results